poisar

Stocks · News reference

Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $750

BenzingaJul 31, 2026, 2:27 PMBenzinga Newsdesk

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $700 to $750.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 31, 2026, 2:27 PM
Checked
Jul 31, 2026, 2:27 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolAug 21, 2026, 11:02 AMAndy Gould

    IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?

    The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.

    Read original at the-motley-fool